<DOC>
	<DOCNO>NCT02130531</DOCNO>
	<brief_summary>The purpose study characterize emixustat hydrochloride pharmacokinetic pharmacodynamic parameter subject geographic atrophy associate dry age-related macular degeneration .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Study Emixustat Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration</brief_title>
	<detailed_description>This multi-center , randomize , mask , multiple-dose , crossover study pharmacokinetics emixustat hydrochloride ( HCl ) subject geographic atrophy ( GA ) associate dry age-related macular degeneration ( AMD ) . Subjects receive study drug multiple dose period crossover design , serve control . There 21-28 day washout period dose period . The final Study Exit visit 21 28 day subject 's last dose study drug end final dosing period .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Males female age â‰¥65 year Clinical diagnosis GA associate AMD Able willing provide write informed consent Able reliably administer oral medication self available assistance Geographic atrophy associate condition AMD History , active high risk develop choroidal neovascularization ( CNV ) either eye Known serious allergy fluorescein sodium injection angiography Prespecified laboratory abnormality screen Treatment investigational study drug within 30 day screen device within 60 day screen Prior participation clinical study emixustat History disease , metabolic dysfunction , chronic immunosuppression , physical examination find Male subject surgically sterile willing practice medically accept method birth control female partner childbearing potential screen 21 day last dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>